Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
260
-
Total 13F shares, excl. options
-
51.8M
-
Shares change
-
-416K
-
Total reported value, excl. options
-
$3.83B
-
Value change
-
-$26.4M
-
Put/Call ratio
-
1.37
-
Number of buys
-
128
-
Number of sells
-
-119
-
Price
-
$74.03
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q3 2022
295 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q3 2022.
HAEMONETICS CORP - Common Stock (HAE) has 260 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.8M shares
.
Largest 10 shareholders include Capital Research Global Investors (6.29M shares), BlackRock Inc. (5.54M shares), WELLINGTON MANAGEMENT GROUP LLP (5.37M shares), VANGUARD GROUP INC (5.2M shares), Neuberger Berman Group LLC (3.89M shares), STATE STREET CORP (1.7M shares), FRANKLIN RESOURCES INC (1.35M shares), Fisher Asset Management, LLC (1.25M shares), SCHRODER INVESTMENT MANAGEMENT GROUP (983K shares), and GEODE CAPITAL MANAGEMENT, LLC (886K shares).
This table shows the top 260 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.